The story of Sildenafil presents a nuanced case for stakeholders in the medicinal sector. While initially a phenomenal success, generating vast sums, the intellectual property end and the subsequent entry of off-brand https://escort421332.idblogz.com/42112047/the-little-copyright-and-big-pharma-a-speculative-play